Patel Chirag, Thomas Gary, Zomorodi Naseem, Zagon Ian S, McLaughlin Patricia J
Department of Neural and Behavioral Sciences, Hershey, PA 17033, USA.
Department of Neurology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
Mult Scler Relat Disord. 2021 May;50:102868. doi: 10.1016/j.msard.2021.102868. Epub 2021 Feb 27.
Multiple sclerosis (MS) is an autoimmune-mediated degenerative disorder with increased peripheral inflammation disrupting the blood brain barrier. With increasing MS-related healthcare costs, the requirement to validate minimally invasive biomarkers has become imperative.
Relapsing-remitting MS patients on disease modifying therapies were consented at the Penn State Health MS Clinic to provide blood samples for analyses of serum cytokines and endogenous opioid peptides, as well as to complete the MSQOL-54 survey.
Serum OGF levels in MS patients on glatiramer acetate (mean = 326 pg/ml), dimethyl fumarate (mean = 193.3 pg/ml) and natalizumab (mean = 393.4 pg/ml) were significantly elevated (p < 0.01) compared to healthy controls (mean = 98.46 pg/ml). Individuals with elevated OGF levels also had increased levels of TNFα (r = 0.78) and IL-17A (r = 0.81). Only patients treated with glatiramer acetate had significant (p < 0.01) elevations in serum β-endorphin levels. Analyses of MS-QoL 54 data showed no significant differences in physical or mental composite scores between treatment groups. However, serum levels of β-endorphin had a direct correlation with physical health composite score (r = 0.70) in all treatments. Serum vitamin D levels had an indirect relationship with 25-foot walk test times (r = 0.47).
Both regression and cohort data suggest that serum levels of OGF, β-endorphin, and vitamin D are potential biomarkers for physical disease status in MS.
多发性硬化症（MS）是一种自身免疫介导的退行性疾病，外周炎症增加会破坏血脑屏障。随着与MS相关的医疗成本不断增加，验证微创生物标志物的需求变得势在必行。
宾夕法尼亚州立大学健康MS诊所同意对接受疾病修饰疗法的复发缓解型MS患者进行采血，以分析血清细胞因子和内源性阿片肽，并完成MSQOL-54调查。
与健康对照组（平均=98.46 pg/ml）相比，接受醋酸格拉替雷（平均=326 pg/ml）、富马酸二甲酯（平均=193.3 pg/ml）和那他珠单抗（平均=393.4 pg/ml）治疗的MS患者血清OGF水平显著升高（p<0.01）。OGF水平升高的个体中，TNFα（r=0.78）和IL-17A（r=0.81）水平也升高。只有接受醋酸格拉替雷治疗的患者血清β-内啡肽水平有显著（p<0.01）升高。MS-QoL 54数据的分析显示，各治疗组之间的身体或精神综合评分无显著差异。然而，在所有治疗中，血清β-内啡肽水平与身体健康综合评分直接相关（r=0.70）。血清维生素D水平与25英尺步行测试时间呈间接关系（r=0.47）。
回归分析和队列数据均表明，血清OGF、β-内啡肽和维生素D水平可能是MS身体疾病状态的生物标志物。
